The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.

Parkinson's disease is a chronic progressive neurological disease that affects a small area of nerve cells (neurons) in an area of the brain known as the substantia nigra. These cells normally ...

The main neuropathological feature of Parkinson's disease is the loss of dopaminergic neurons in the substantia nigra pars compacta. Specifically, dopaminergic neurons in the ventral tier of the ...

New research reveals Parkinson’s disease may originate in the kidneys, where toxic protein buildup travels to the brain—offering fresh hope for early detection and treatment.

Currently dopamine replacement medications, like levodopa and dopamine agonists, are the primary treatment for Parkinson's ...

Putting the brakes on an enzyme might rescue neurons that are dying in Parkinson's disease, stabilizing the progression of ...

Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine ...

Diagnosing Parkinson's disease has always been a race against time. The later it’s found, the harder it is to treat.

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

The major symptoms of Parkinson's disease arise due to the degeneration of neurons (brain cells) in the substantia nigra of the basal ganglia of the brain. This region primarily regulates movements.

April is National Parkinson’s Disease Awareness month; ... “Basically, the part of the… brain, so the substantia nigra, you stop having the ability to make dopamine over time.